glp-1 news today cardiovascular outcomes 2025 november Frontiers Cardiac Trials | Lowering CV

Check your "Action Center" for a notification

Key findings include: Diabetic patients on Semaglutide medications are over four times more likely to develop NAION

Though causative genes have been identified, the mechanisms through which the genetic mutations induce obesity are not completely understood in all cases[138]

Youve Reached a Natural Set Point Your body has a built-in "set point" a weight range it naturally tries to maintain

T3 thyroid hormone is roughly 3 to 4 times more potent than T4 on a microgram-for-microgram basis, which is why even small changes in T3 dosing can make a big difference in how you feel

Roberto Amado, MD, MHA, prescribe oral semaglutide for eligible patients as part of a comprehensive weight management plan